Greg Cook is the senior director of access, policy and advocacy at Bristol Myers Squibb Australia. In a Q&A with BioPharmaDispathch, he discusses the 'access' challenge and the need for the health technology assessment review to focus on achieving the 'North Star' for patients.
Faster patient access must be the 'North Star' for HTA review
March 22, 2023 Latest NewsBioPharmaBioPharmaDispatch Executive
Latest Video
New Stories
-
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News -
Parsimony has unfortunately become an enduring test of the institution's legitimacy
December 20, 2025 - - Latest News -
PBAC delivers a broad range of outcomes in November, including for obesity
December 20, 2025 - - Latest News -
Takeda’s next-generation psoriasis therapy delivers landmark Phase 3 results
December 19, 2025 - - Latest News -
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech

